Dr. Sehouli Discusses Trial of Secondary Cytoreductive Surgery in Ovarian Cancer

Jalid Sehouli, MD
Published: Tuesday, Nov 07, 2017



Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, discusses a trial of secondary cytoreductive surgery in patients with ovarian cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).

Sehouli says that surgery is the cornerstone of primary treatment for ovarian cancer, followed by subsequent chemotherapy with platinum combinations. The role of surgery in the relapsed setting is not as defined though, Sehouli adds.

In a randomized controlled phase III study, secondary cytoreductive surgery was evaluated in patients with platinum-sensitive recurrent ovarian cancer.
 


Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, discusses a trial of secondary cytoreductive surgery in patients with ovarian cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).

Sehouli says that surgery is the cornerstone of primary treatment for ovarian cancer, followed by subsequent chemotherapy with platinum combinations. The role of surgery in the relapsed setting is not as defined though, Sehouli adds.

In a randomized controlled phase III study, secondary cytoreductive surgery was evaluated in patients with platinum-sensitive recurrent ovarian cancer.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x